Mark A. Pattoli

1.5k total citations
14 papers, 891 citations indexed

About

Mark A. Pattoli is a scholar working on Immunology, Molecular Biology and Cancer Research. According to data from OpenAlex, Mark A. Pattoli has authored 14 papers receiving a total of 891 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Mark A. Pattoli's work include NF-κB Signaling Pathways (6 papers), Galectins and Cancer Biology (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Mark A. Pattoli is often cited by papers focused on NF-κB Signaling Pathways (6 papers), Galectins and Cancer Biology (3 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Mark A. Pattoli collaborates with scholars based in United States, Germany and India. Mark A. Pattoli's co-authors include James R. Burke, Kim W. McIntyre, Yuping Qiu, F. Christopher Zusi, John F. MacMaster, Kurt R. Gregor, Patrick Brassil, Wendy Clarke, Xiaoxia Yang and Joann Strnad and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Analytical Chemistry.

In The Last Decade

Mark A. Pattoli

14 papers receiving 868 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark A. Pattoli United States 10 411 368 296 230 103 14 891
Brian Bolognese United States 18 522 1.3× 214 0.6× 380 1.3× 265 1.2× 75 0.7× 34 1.2k
Sheri L. Bonar United States 13 455 1.1× 263 0.7× 262 0.9× 152 0.7× 41 0.4× 15 763
Narmada Shenoy United States 11 532 1.3× 145 0.4× 138 0.5× 240 1.0× 57 0.6× 17 990
Michelle L. Kraus United States 7 466 1.1× 129 0.4× 101 0.3× 447 1.9× 96 0.9× 9 1.1k
Gregory W. Peet United States 11 487 1.2× 245 0.7× 240 0.8× 195 0.8× 121 1.2× 13 863
Chaoxin Hu United States 13 434 1.1× 128 0.3× 97 0.3× 367 1.6× 50 0.5× 18 920
Jun Ohsumi Japan 18 535 1.3× 81 0.2× 386 1.3× 311 1.4× 111 1.1× 31 1.2k
Moses M. Kasembeli United States 17 659 1.6× 127 0.3× 223 0.8× 498 2.2× 82 0.8× 25 1.3k
Masamichi Inami Japan 17 331 0.8× 57 0.2× 472 1.6× 173 0.8× 118 1.1× 41 1.0k
Jiqin Lian China 19 905 2.2× 300 0.8× 119 0.4× 207 0.9× 65 0.6× 43 1.3k

Countries citing papers authored by Mark A. Pattoli

Since Specialization
Citations

This map shows the geographic impact of Mark A. Pattoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Pattoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Pattoli more than expected).

Fields of papers citing papers by Mark A. Pattoli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Pattoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Pattoli. The network helps show where Mark A. Pattoli may publish in the future.

Co-authorship network of co-authors of Mark A. Pattoli

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Pattoli. A scholar is included among the top collaborators of Mark A. Pattoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Pattoli. Mark A. Pattoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Vasta, James D., Gregory Locke, Mark A. Pattoli, et al.. (2019). A High-Throughput BRET Cellular Target Engagement Assay Links Biochemical to Cellular Activity for Bruton’s Tyrosine Kinase. SLAS DISCOVERY. 25(2). 176–185. 9 indexed citations
2.
Zheng, Naiyu, Ian M. Catlett, Kristin Taylor, et al.. (2019). Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS. Analytical Chemistry. 91(13). 8443–8452. 9 indexed citations
3.
Liu, Qingjie, Douglas G. Batt, Charu Chaudhry, et al.. (2018). Conversion of carbazole carboxamide based reversible inhibitors of Bruton’s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series. Bioorganic & Medicinal Chemistry Letters. 28(18). 3080–3084. 12 indexed citations
4.
Gillooly, Kathleen M., Claudine Pulicicchio, Mark A. Pattoli, et al.. (2017). Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. PLoS ONE. 12(7). e0181782–e0181782. 47 indexed citations
5.
Dyckman, Alaric J., Charles M. Langevine, Claude Quesnelle, et al.. (2010). Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: Synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. Bioorganic & Medicinal Chemistry Letters. 21(1). 383–386. 7 indexed citations
6.
Kempson, James, Junqing Guo, Jagabandhu Das, et al.. (2009). Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IκB kinase. Bioorganic & Medicinal Chemistry Letters. 19(10). 2646–2649. 16 indexed citations
7.
Belema, Makonen, Amy Bunker, Van N. Nguyen, et al.. (2007). Synthesis and structure–activity relationship of imidazo(1,2-a)thieno(3,2-e)pyrazines as IKK-β inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(15). 4284–4289. 26 indexed citations
8.
Beaulieu, Françis, Carl Ouellet, Edward H. Ruediger, et al.. (2006). Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(5). 1233–1237. 45 indexed citations
9.
Pattoli, Mark A., John F. MacMaster, Kurt R. Gregor, & James R. Burke. (2005). Collagen and Aggrecan Degradation Is Blocked in Interleukin-1-Treated Cartilage Explants by an Inhibitor of IκB Kinase through Suppression of Metalloproteinase Expression. Journal of Pharmacology and Experimental Therapeutics. 315(1). 382–388. 47 indexed citations
10.
Burke, James R., Mark A. Pattoli, Kurt R. Gregor, et al.. (2003). BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice. Journal of Biological Chemistry. 278(3). 1450–1456. 439 indexed citations
11.
McIntyre, Kim W., David J. Shuster, Kathleen M. Gillooly, et al.. (2003). A highly selective inhibitor of IκB kinase, BMS‐345541, blocks both joint inflammation and destruction in collagen‐induced arthritis in mice. Arthritis & Rheumatism. 48(9). 2652–2659. 185 indexed citations
12.
Berenson, Charles S., et al.. (1998). Gangliosides of monocyte-derived macrophages of adults with advanced HIV infection show reduced surface accessibility. Journal of Leukocyte Biology. 64(3). 311–321. 5 indexed citations
13.
Fakih, Mohamad G., Timothy F. Murphy, Mark A. Pattoli, & Charles S. Berenson. (1997). Specific binding of Haemophilus influenzae to minor gangliosides of human respiratory epithelial cells. Infection and Immunity. 65(5). 1695–1700. 32 indexed citations
14.
Berenson, Charles S., et al.. (1996). A monoclonal antibody to human macrophage gangliosides inhibits macrophage migration. Journal of Leukocyte Biology. 59(3). 371–379. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian Bolognese Breakdown of academic impact, for papers by Sheri L. Bonar Breakdown of academic impact, for papers by Narmada Shenoy Breakdown of academic impact, for papers by Michelle L. Kraus Breakdown of academic impact, for papers by Gregory W. Peet Breakdown of academic impact, for papers by Chaoxin Hu Breakdown of academic impact, for papers by Jun Ohsumi Breakdown of academic impact, for papers by Moses M. Kasembeli Breakdown of academic impact, for papers by Masamichi Inami Breakdown of academic impact, for papers by Jiqin Lian
Rankless by CCL
2026